Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Relisted on Nasdaq

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vermillion today said that Nasdaq has approved its application to get relisted on the exchange's Global Market.

As a result, the company's common stock began trading on the Nasdaq under ticker symbol "VRML" this morning.

Vermillion's stock had been trading on the Pink Sheets since being delisted in September 2008 for failing to meet minimum listing requirements. The Fremont, Calif.-based molecular diagnostics company soon after filed for Chapter 11 bankruptcy protection. Earlier this year, it emerged from bankruptcy protection, which had followed clearance from the US Food and Drug Administration for its OVA1 triage ovarian cancer diagnostic test.

"With today's announcement of Vermillion's relisting on Nasdaq, we expect to provide our shareholders with enhanced market maker support, more efficient access to institutional investors and investment capital, improved liquidity, and greater visibility for the company within the investment community — all part of our strategy to increase shareholder value," Sandra Gardiner, VP and CFO of Vermillion, said in a statement.

In early Tuesday trade, Vermillion's shares were up 4 percent at $12.22.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.